DLB
MCID: DMN031
MIFTS: 65

Dementia, Lewy Body (DLB)

Categories: Genetic diseases, Mental diseases, Rare diseases

Aliases & Classifications for Dementia, Lewy Body

MalaCards integrated aliases for Dementia, Lewy Body:

Name: Dementia, Lewy Body 57 43 72 13
Lewy Body Dementia 57 12 20 43 53 72 36 29 6 42 15 39 17
Lewy Body Disease 12 20 43 54 44 70
Diffuse Lewy Body Disease 57 12 20 43 72
Dementia with Lewy Bodies 12 73 43 53 15
Dlb 57 20 43 72
Autosomal Dominant Diffuse Lewy Body Disease 20 70
Dementia, Lewy Body, Susceptibility to 29 6
Diffuse Lewy Body Disease with Gaze Palsy 72
Lewy Body Variant of Alzheimer Disease 72
Lewy Body Dementia, Susceptibility to 57
Senile Dementia of the Lewy Body Type 12
Dementia of the Lewy Body Type 43
Lewy Body Type Senile Dementia 72
Dysphasic Dementia Hereditary 72
Cortical Lewy Body Disease 72
Lewy Bodies 29
Lbd 43

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant

Miscellaneous:
onset in the sixth or seventh decades
phenotypic overlap with parkinson disease
allelic disorder to parkinson disease-1 (park1, )


HPO:

31
dementia, lewy body:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:12217
OMIM® 57 127750
KEGG 36 H00066
ICD9CM 34 331.82
MeSH 44 D020961
NCIt 50 C84826
SNOMED-CT 67 192808003
ICD10 32 G31.83
UMLS 70 C0752347 C2931906

Summaries for Dementia, Lewy Body

MedlinePlus : 42 What is Lewy body dementia (LBD)? Lewy body dementia (LBD) is one of the most common types of dementia in older adults. Dementia is a loss of mental functions that is severe enough to affect your daily life and activities. These functions include Memory Language skills Visual perception (your ability to make sense of what you see) Problem solving Trouble with everyday tasks The ability to focus and pay attention What are the types of Lewy body dementia (LBD)? There are two types of LBD: dementia with Lewy bodies and Parkinson's disease dementia. Both types cause the same changes in the brain. And, over time, they can cause similar symptoms. The main difference is in when the cognitive (thinking) and movement symptoms start. Dementia with Lewy bodies causes problems with thinking ability that seem similar to Alzheimer's disease. Later, it also causes other symptoms, such as movement symptoms, visual hallucinations, and certain sleep disorders. It also causes more trouble with mental activities than with memory. Parkinson's disease dementia starts as a movement disorder. It first causes the symptoms of Parkinson's disease: slowed movement, muscle stiffness, tremor, and a shuffling walk. Later on, it causes dementia. What causes Lewy body dementia (LBD)? LBD happens when Lewy bodies build up in parts of the brain that control memory, thinking, and movement. Lewy bodies are abnormal deposits of a protein called alpha-synuclein. Researchers don't know exactly why these deposits form. But they do know that other diseases, such as Parkinson's disease, also involve a build-up of that protein. Who is at risk for Lewy body dementia (LBD)? The biggest risk factor for LBD is age; most people who get it are over age 50. People who have a family history of LBD are also at higher risk. What are the symptoms of Lewy body dementia (LBD)? LBD is a progressive disease. This means that the symptoms start slowly and get worse over time. The most common symptoms include changes in cognition, movement, sleep, and behavior: Dementia, which is a loss of mental functions that is severe enough to affect your daily life and activities Changes in concentration, attention, alertness, and wakefulness. These changes usually happen from day to day. But sometimes they can also happen throughout the same day. Visual hallucinations, which means seeing things that are not there Problems with movement and posture, including slowness of movement, difficulty walking, and muscle stiffness. These are called parkinsonian motor symptoms. REM sleep behavior disorder, a condition in which a person seems to act out dreams. It may include vivid dreaming, talking in one's sleep, violent movements, or falling out of bed. This may be the earliest symptom of LBD in some people. It can appear several years before any other LBD symptoms. Changes in behavior and mood, such as depression, anxiety, and apathy (a lack of interest in normal daily activities or events) In the early stages of LBD, symptoms can be mild, and people can function fairly normally. As the disease gets worse, people with LBD need more help due to problems with thinking and movement. In the later stages of the disease, they often cannot care for themselves. How is Lewy body dementia (LBD) diagnosed? There isn't one test that can diagnose LBD. It is important to see an experienced doctor to get a diagnosis. This would usually be specialist such as a neurologist. The doctor will Do a medical history, including taking a detailed account of the symptoms. The doctor will talk to both the patient and caregivers. Do physical and neurological exams Do tests to rule out other conditions that could cause similar symptoms. These could include blood tests and brain imaging tests. Do neuropsychological tests to evaluate memory and other cognitive functions LBD can be hard to diagnose, because Parkinson's disease and Alzheimer's disease cause similar symptoms. Scientists think that Lewy body disease might be related to these diseases, or that they sometimes happen together. It's also important to know which type of LBD a person has, so the doctor can treat that type's particular symptoms. It also helps the doctor understand how the disease will affect the person over time. The doctor makes a diagnosis based on when certain symptoms start: If cognitive symptoms start within a year of movement problems, the diagnosis is dementia with Lewy bodies If cognitive problems start more than a year after the movement problems, the diagnosis is Parkinson's disease dementia What are the treatments for Lewy body dementia (LBD)? There is no cure for LBD, but treatments can help with the symptoms: Medicines may help with some of the cognitive, movement, and psychiatric symptoms Physical therapy can help with movement problems Occupational therapy may help find ways to more easily do everyday activities Speech therapy may help with swallowing difficulties and trouble speaking loudly and clearly Mental health counseling can help people with LBD and their families learn how to manage difficult emotions and behaviors. It can also help them plan for the future. Music or art therapy may reduce anxiety and improve well-being Support groups can also be helpful for people with LBD and their caregivers. Support groups can give emotional and social support. They are also a place where people can share tips about how to deal with day-to-day challenges. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Dementia, Lewy Body, also known as lewy body dementia, is related to parkinson disease 4, autosomal dominant and parkinson disease 1, autosomal dominant, and has symptoms including seizures, tremor and back pain. An important gene associated with Dementia, Lewy Body is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Pathways of neurodegeneration - multiple diseases and Circadian entrainment. The drugs Modafinil and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and skin, and related phenotypes are dementia and visual hallucinations

Disease Ontology : 12 A dementia that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.

MedlinePlus Genetics : 43 Dementia with Lewy bodies is a nervous system disorder characterized by a decline in intellectual function (dementia), a group of movement problems known as parkinsonism, visual hallucinations, sudden changes (fluctuations) in behavior and intellectual ability, and acting out dreams while asleep (REM sleep behavior disorder). This condition typically affects older adults, most often developing between ages 50 and 85. The life expectancy of individuals with dementia with Lewy bodies varies; people typically survive about 5 to 7 years after they are diagnosed.REM sleep behavior disorder may be the first sign of dementia with Lewy bodies. It can occur years before other symptoms appear. Individuals with REM sleep behavior disorder act out their dreams, talking and moving in their sleep when they should be still. This behavior becomes less pronounced as dementia with Lewy bodies worsens and additional features develop.Dementia is often the second major feature to develop in dementia with Lewy bodies. Initially, this intellectual decline may be mild or seem to come and go. In this condition, dementia often leads to impaired ability to perform visual-spatial tasks such as assembling puzzles. Affected individuals may also have poor problem-solving skills (executive functioning), speech difficulties, and reduced inhibitions. Problems with memory typically do not occur until later.Most people with dementia with Lewy bodies experience visual hallucinations, which often involve people or animals. Fluctuations in behavior and thought processes (cognition) include sudden changes in attention, unintelligible speech, and brief episodes of altered consciousness that may appear as staring spells.Parkinsonism is usually the last major feature to develop in people with dementia with Lewy bodies, although it can appear earlier in some individuals. The movement problems typically include tremors, rigidity, unusually slow movement (bradykinesia), and impaired balance and coordination (postural instability). Affected individuals may require walking aids or wheelchair assistance over time.Individuals with dementia with Lewy bodies may also experience a sharp drop in blood pressure upon standing (orthostatic hypotension), fainting episodes (syncope), reduced sense of smell, increased saliva production and drooling, difficulty controlling the flow of urine (incontinence), or constipation.

GARD : 20 Lewy body dementia is one of the most common forms of progressive dementia. People affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. Although the exact cause of Lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("Lewy bodies") accumulate in the brain. Lewy body dementia usually occurs sporadically in people with no family history of the condition. Rarely, more than one family member may be affected. There is currently no cure for Lewy body dementia; however, medications may be available to help manage the associated symptoms.

OMIM® : 57 Dementia with Lewy bodies (DLB) is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Pathologically, Lewy bodies are present in a pattern more widespread than usually observed in Parkinson disease (see PD; 168600). Alzheimer disease (AD; 104300)-associated pathology and spongiform changes may also be seen (McKeith et al., 1996; Mizutani, 2000; McKeith et al., 2005). (127750) (Updated 05-Apr-2021)

NINDS : 53 Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central features of DLB include progressive cognitive decline, “fluctuations” in alertness and attention, visual hallucinations, and parkinsonian motor symptoms, such as slowness of movement, difficulty walking, or rigidity.  People may also suffer from depression.  The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control.  Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases.  These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time.  DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.

KEGG : 36 Lewy Body dementia (LDB) is neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. It is the second most-common degenerative dementia after Alzheimer's disease. Progressive accumulation of alpha-synuclein- and ubiquitin-positive Lewy Bodies is seen in the brainstem, the limbic system or cortical and subcortical regions, depending on disease subtype. The genetic risk factors include alpha-synuclein mutations and SNCA locus triplicationslocus triplications. Mutations of leucine-rich repeat kinase 2 (LRRK2) and the glucocerebrosidase (GBA) gene have also been implicated in familial DLB.

UniProtKB/Swiss-Prot : 72 Dementia, Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

Wikipedia : 73 Dementia with Lewy bodies (DLB) is a type of dementia accompanied by changes in sleep, behavior,... more...

Related Diseases for Dementia, Lewy Body

Diseases related to Dementia, Lewy Body via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 359)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 4, autosomal dominant 32.7 TH SNCA SLC6A3
2 parkinson disease 1, autosomal dominant 32.4 SNCA PRKN MAPT LRRK2 GBA
3 parkinsonism 32.4 SNCA SLC6A3 PARK7 MAPT LRRK2 LOC106627981
4 parkinson disease 21 32.1 PRKN LRRK2
5 tremor 31.5 SNCA PRKN LRRK2 LOC106627981 GBA
6 corticobasal degeneration 31.4 MAPT GBA
7 essential tremor 31.3 SNCA SLC6A3 PRKN MAPT LRRK2 GBA
8 anxiety 31.3 TH SNCA SLC6A3 MAOB CYP2D6 APP
9 rem sleep behavior disorder 31.2 SNCA SLC6A3 PRKN MAPT LRRK2 GBA
10 neuroblastoma 31.2 TH SNCA PRNP MAPT APP ACHE
11 hydrocephalus 31.2 SLC6A3 MAPT GBA APP APOE
12 early-onset parkinson's disease 31.1 TH SNCA PRKN PARK7 LRRK2 LOC106627981
13 normal pressure hydrocephalus 31.1 MAPT APP APOE
14 leukoencephalopathy, hereditary diffuse, with spheroids 31.1 SNCA PRNP PRKN MAPT APP
15 mild cognitive impairment 31.1 MAPT BCHE APP APOE
16 pick disease of brain 31.1 SNCAIP SNCA PRNP PRKN PARK7 MAPT
17 huntington disease 31.1 TH SNCA PRNP MAPT MAOB APP
18 cerebral amyloid angiopathy, cst3-related 31.1 SNCA PRNP MAPT APP APOE
19 semantic dementia 31.0 MAPT APOE
20 creutzfeldt-jakob disease 31.0 SNCA PRNP PARK7 MAPT APP APOE
21 sleep disorder 31.0 TH SNCA SLC6A3 SLC18A2 MAPT LRRK2
22 simultanagnosia 31.0 MAPT APOE ACHE
23 nominal aphasia 31.0 MAPT APOE ACHE
24 binswanger's disease 31.0 MAPT APP APOE ACHE
25 agraphia 31.0 PRNP MAPT APOE ACHE
26 early-onset, autosomal dominant alzheimer disease 31.0 MAPT APP APOE
27 fatal familial insomnia 31.0 SNCA PRNP MAPT APP
28 ideomotor apraxia 31.0 SNCA PRNP MAPT BCHE APOE
29 frontotemporal dementia 30.9 SNCB SNCA PRNP MAPT LRRK2 BCHE
30 kufor-rakeb syndrome 30.9 SNCA SLC6A3 PRKN PARK7 LRRK2 GBA
31 parkinson disease 2, autosomal recessive juvenile 30.9 SNCA PRKN PARK7 LRRK2 APOE
32 apraxia 30.9 SLC6A3 MAPT APOE
33 down syndrome 30.9 MAPT APP APOE ACHE
34 olivopontocerebellar atrophy 30.9 TH SNCA SLC6A3 MAPT
35 restless legs syndrome 30.9 TH SNCA SLC6A3 PRKN MAPT MAOB
36 personality disorder 30.9 TH SLC6A3 MAOB
37 posterior cortical atrophy 30.9 MAPT APOE
38 alzheimer disease 2 30.9 MAPT APP APOE
39 postencephalitic parkinson disease 30.9 TH SNCA SLC6A3 PRKN PARK7 MAPT
40 dementia 30.9 TH SNCG SNCB SNCAIP SNCA SLC6A3
41 obsessive-compulsive disorder 30.9 SLC6A3 MAOB CYP2D6 APOE
42 central nervous system disease 30.9 SNCA SLC6A3 SLC18A2 PRNP MAPT APP
43 multiple system atrophy 1 30.9 TH SNCG SNCB SNCA SLC6A3 PRNP
44 capgras syndrome 30.8 SNCA BCHE
45 amnestic disorder 30.8 MAPT BCHE APP APOE ACHE
46 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 30.8 PRNP MAPT
47 amyloidosis 30.8 SNCA PRNP MAPT APP APOE
48 aphasia 30.8 SNCB SNCA PRNP MAPT LRRK2 APP
49 pure autonomic failure 30.8 TH SNCA MAOB ACHE
50 attention deficit-hyperactivity disorder 30.8 TH SNCA SLC6A3 SLC18A2 PRKN MAOB

Graphical network of the top 20 diseases related to Dementia, Lewy Body:



Diseases related to Dementia, Lewy Body

Symptoms & Phenotypes for Dementia, Lewy Body

Human phenotypes related to Dementia, Lewy Body:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 dementia 31 HP:0000726
2 visual hallucinations 31 HP:0002367
3 parkinsonism 31 HP:0001300
4 fluctuations in consciousness 31 HP:0007159
5 lewy bodies 31 HP:0100315
6 delusions 31 HP:0000746

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Neurologic Central Nervous System:
visual hallucinations
parkinsonism
fluctuations in consciousness
delusions
progressive dementia
more

Clinical features from OMIM®:

127750 (Updated 05-Apr-2021)

UMLS symptoms related to Dementia, Lewy Body:


seizures; tremor; back pain; headache; syncope; pain; chronic pain; sciatica; vertigo/dizziness; sleeplessness; hallucinations, visual

MGI Mouse Phenotypes related to Dementia, Lewy Body:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ACHE APOE APP GBA LRRK2 MAOB
2 homeostasis/metabolism MP:0005376 10.39 ACHE APOE APP BCHE GBA LRRK2
3 cellular MP:0005384 10.34 APOE APP GBA LRRK2 MAOB MAPT
4 growth/size/body region MP:0005378 10.29 ACHE APOE APP GBA MAPT PARK7
5 mortality/aging MP:0010768 10.25 ACHE APOE APP BCHE GBA LRRK2
6 nervous system MP:0003631 10.22 ACHE APOE APP GBA LRRK2 MAOB
7 integument MP:0010771 10.13 APOE APP GBA LRRK2 MAPT PRKN
8 muscle MP:0005369 9.97 ACHE APOE APP MAPT PRKN PRNP
9 no phenotypic analysis MP:0003012 9.96 ACHE APOE APP LRRK2 MAPT PRKN
10 normal MP:0002873 9.85 APP GBA LRRK2 MAPT PRKN PRNP
11 skeleton MP:0005390 9.65 APOE APP GBA LRRK2 PARK7 PRKN
12 taste/olfaction MP:0005394 9.02 APOE MAPT SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Dementia, Lewy Body

Drugs for Dementia, Lewy Body (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
2
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
3
Donepezil Approved Phase 4 120014-06-4 3152
4
Memantine Approved, Investigational Phase 4 19982-08-2 4054
5
Zoledronic Acid Approved Phase 4 118072-93-8 68740
6
Corticosterone Experimental Phase 4 50-22-6 5753
7 Central Nervous System Stimulants Phase 4
8 Cholinergic Agents Phase 4
9 Neurotransmitter Agents Phase 4
10 Nootropic Agents Phase 4
11 Cholinesterase Inhibitors Phase 4
12 Dopamine Agents Phase 4
13 Excitatory Amino Acid Antagonists Phase 4
14 Antiparkinson Agents Phase 4
15 Fluorodeoxyglucose F18 Phase 4
16 Anti-Inflammatory Agents Phase 4
17
Galantamine Approved Phase 3 357-70-0 9651
18
Furosemide Approved, Vet_approved Phase 3 54-31-9 3440
19 Radiopharmaceuticals Phase 3
20 Sodium Potassium Chloride Symporter Inhibitors Phase 3
21 Dihydroxyphenylalanine Phase 3
22 diuretics Phase 3
23
Prazosin Approved Phase 1, Phase 2 19216-56-9 4893
24
Terazosin Approved Phase 1, Phase 2 63590-64-7 5401
25
Ambroxol Approved, Investigational Phase 2 18683-91-5
26 Orange Approved Phase 2
27
Aspartic acid Approved, Nutraceutical Phase 2 56-84-8 5960
28 Dopamine agonists Phase 1, Phase 2
29 N-Methylaspartate Phase 2
30 Adrenergic alpha-Antagonists Phase 1, Phase 2
31 Adrenergic alpha-1 Receptor Antagonists Phase 1, Phase 2
32 Adrenergic Antagonists Phase 1, Phase 2
33 Adrenergic Agents Phase 1, Phase 2
34 Antihypertensive Agents Phase 1, Phase 2
35 Respiratory System Agents Phase 2
36 Expectorants Phase 2
37
Entacapone Approved, Investigational Phase 1 130929-57-6 5281081
38
Carbidopa Approved Phase 1 28860-95-9 34359
39 Catechol Phase 1
40 Aromatic Amino Acid Decarboxylase Inhibitors Phase 1
41
Acetylcholine Approved, Investigational 51-84-3 187
42
Rivastigmine Approved, Investigational 123441-03-2 77991
43
Ethanol Approved 64-17-5 702
44
Acetylcysteine Approved, Investigational 616-91-1 12035
45
Hydroxocobalamin Approved 13422-51-0 11953898 15589840
46
Dextromethorphan Approved 125-71-3 5360696 5362449
47
Quinidine Approved, Investigational 56-54-2 441074
48
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
49
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
50
2-Phenylethanol Experimental 60-12-8 6054

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Completed NCT02345213 Phase 4 E2020;Placebo
2 An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies Completed NCT01023672 Phase 4 Armodafinil
3 A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
4 TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease Recruiting NCT03924414 Phase 4 Zoledronic Acid 5Mg/Bag 100Ml Inj
5 Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title) Recruiting NCT04117178 Phase 4 Donepezil;Memantine
6 Longitudinal Imaging Biomarkers of Disease Progression in DLB Enrolling by invitation NCT03582488 Phase 4 18F-Flortaucipir
7 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
8 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
9 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Completed NCT01278407 Phase 3 Donepezil 5 mg;Donepezil 10 mg;Donepezil matched placebo
10 An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies Completed NCT00230997 Phase 3 Galantamine
11 Oculomotor Recording in the Contribution to the Early Differential Diagnosis of Dementia With Lewy Bodies and Alzheimer's Disease Completed NCT01577394 Phase 3
12 GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title Completed NCT00209456 Phase 3 DatSCAN
13 18F-DOPA II - PET Imaging Optimization Recruiting NCT04706910 Phase 3 18F-DOPA;Furosemide Injection
14 A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB) Terminated NCT02928445 Phase 2, Phase 3 RVT-101 35 mg;RVT-101 70 mg
15 Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) Completed NCT03305809 Phase 2 LY3154207;Placebo
16 Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers Completed NCT01503944 Phase 1, Phase 2 18F-AV-133;18F-AV-45
17 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies Completed NCT00598650 Phase 2 E2020
18 A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD) Completed NCT02708186 Phase 2 Nelotanserin;Placebo
19 A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB) Completed NCT02669433 Phase 2 RVT-101 35 mg;RVT-101 70 mg;Placebo
20 A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies Completed NCT03467152 Phase 2 E2027;Placebo
21 Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II Completed NCT00543855 Phase 2 3 mg Donepezil hydrochloride;5 mg Donepezil hydrochloride;10 mg Donepezil hydrochloride;Placebo
22 Imaging Inflammation in Patients With Diffuse Lewy Body Disease Completed NCT02702102 Phase 2 11C-PBR28
23 A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia Completed NCT02910102 Phase 2 RVT-101 35 mg;Placebo
24 A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00630500 Phase 2 Memantine;Placebo
25 A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH) Completed NCT02640729 Phase 2 Nelotanserin;Placebo
26 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment Completed NCT03538522 Phase 2 N-831(Traneurocin) 10 mg QD;NA-831 (Traneurocin) 20 mg QD;NA-831 (Traneurocin) 40 mg QD;Placebo oral capsule QD
27 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies (DLB) Recruiting NCT04002674 Phase 2 Placebo oral capsule;Nilotinib Oral Capsule
28 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of K0706 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics and Clinical Outcomes in Dementia With Lewy Bodies (DLB) Recruiting NCT03996460 Phase 2 Placebo oral capsule;96 mg of K0706;192 mg K0706
29 A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia Recruiting NCT04148391 Phase 2 Placebo Oral Capsule;NYX-458
30 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (DLB) Active, not recruiting NCT03888222 Phase 2 Placebo Oral Tablet;Bosutinib Oral Tablet
31 A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB) Active, not recruiting NCT04001517 Phase 2 Neflamapimod
32 a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies Not yet recruiting NCT04760860 Phase 1, Phase 2 Terazosin Hydrochloride
33 A Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With Lewybodies Not yet recruiting NCT04588285 Phase 2 Ambroxol;Placebo
34 An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology Not yet recruiting NCT04764669 Phase 2 E2027
35 Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia Not yet recruiting NCT04405596 Phase 1, Phase 2 Ambroxol Hydrochloride
36 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 Co-administered With CST-107 on the Central Nervous System in Subjects With Neurodegenerative Disorders Not yet recruiting NCT04739423 Phase 2 CST-103, CST-107, matching placebo
37 An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder Terminated NCT02871427 Phase 2 Nelotanserin
38 A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Assess the Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies Withdrawn NCT03592862 Phase 2 HTL0018318;Placebo
39 An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Subjects Completed NCT04023877 Phase 1 E2027
40 Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood α-Synuclein Completed NCT02281474 Phase 1 Nilotinib
41 [18F]F-DOPA Imaging in Patients With Autonomic Failure Recruiting NCT04246437 Phase 1 [18F]FDOPA;Carbidopa 200mg oral dose;Entacapone 400mg oral dose
42 Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies Unknown status NCT01256905 Armodafinil
43 Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD) Unknown status NCT01993628
44 Rate of Alpha-synuclein in Cerebrospinal Fluid to Differentiate Patient With Alzheimer's Disease From Those With Lewy Body Disease. Unknown status NCT01876459
45 Correlation Between Gait Disorders and Neuropsychological Profile in Patients With Alzheimer's Disease and Lewy Body Disease Unknown status NCT03399591
46 Studies of Brain and Body Interaction at Rutgers University Unknown status NCT03672266
47 Co-LEsions in Alzheimer Disease and Related Disorders Unknown status NCT02052947
48 Optical Coherence Tomography in Cerebral Amyloidosis Unknown status NCT03472482
49 Double Blind, Randomised, Dual Centre, Crossover, Pilot Trial of Bilateral Nucleus Basalis of Meynert Deep Brain Stimulation to Improve Cognitive Deficits in Patients With Dementia With Lewy Bodies. Completed NCT02263937
50 Movement and Music Intervention for Individuals With Dementia Completed NCT03121950

Search NIH Clinical Center for Dementia, Lewy Body

Cochrane evidence based reviews: lewy body disease

Genetic Tests for Dementia, Lewy Body

Genetic tests related to Dementia, Lewy Body:

# Genetic test Affiliating Genes
1 Lewy Body Dementia 29 GBA SNCA SNCB
2 Lewy Bodies 29
3 Dementia, Lewy Body, Susceptibility to 29

Anatomical Context for Dementia, Lewy Body

MalaCards organs/tissues related to Dementia, Lewy Body:

40
Brain, Eye, Skin, Cortex, Heart, Nk Cells, Occipital Lobe

Publications for Dementia, Lewy Body

Articles related to Dementia, Lewy Body:

(show top 50) (show all 1058)
# Title Authors PMID Year
1
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. 54 6 57 61
14755719 2004
2
Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. 57 54 6
18413475 2008
3
Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication. 6 57
18852445 2008
4
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. 57 6
18332251 2008
5
Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. 6 57
18195271 2008
6
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. 6 57
16358335 2006
7
Beta-synuclein gene alterations in dementia with Lewy bodies. 6 57
15365127 2004
8
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. 54 57
18335262 2008
9
A novel PSEN2 mutation associated with a peculiar phenotype. 57 61
18427071 2008
10
Research priorities of caregivers and individuals with dementia with Lewy bodies: An interview study. 42 61
33027276 2020
11
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. 57
29743672 2018
12
A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. 6
25003242 2014
13
Mosaicism of alpha-synuclein gene rearrangements: report of two unrelated cases of early-onset parkinsonism. 6
24552873 2014
14
The L444P GBA mutation is associated with early-onset Parkinson's disease in Mexican Mestizos. 6
23448517 2013
15
Detection of copy number changes in genes associated with Parkinson's disease in Iranian patients. 6
23880019 2013
16
A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders. 6
22713811 2013
17
Gaucher disease: frequency of the N370S mutation in the Greek population. 6
20662857 2010
18
alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. 6
19833540 2010
19
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. 6
19286695 2009
20
Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. 6
19139307 2009
21
Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. 6
18852449 2008
22
Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. 6
18852448 2008
23
The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. 6
18541817 2008
24
alpha-Synuclein gene duplication is present in sporadic Parkinson disease. 6
17625105 2008
25
LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. 6
18022370 2007
26
Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. 6
17620502 2007
27
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. 6
17251522 2007
28
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. 57
16790605 2006
29
Lrrk2 and Lewy body disease. 57
16437559 2006
30
Biochemical and pathological characterization of Lrrk2. 57
16437584 2006
31
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. 57
16237129 2005
32
A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. 57
15732120 2005
33
The E46K mutation in alpha-synuclein increases amyloid fibril formation. 6
15632170 2005
34
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. 6
15498564 2004
35
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. 6
15451224 2004
36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. 6
15451225 2004
37
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. 6
14755720 2004
38
alpha-Synuclein locus triplication causes Parkinson's disease. 6
14593171 2003
39
Dementia with Lewy bodies: disease concept and genetics. 57
12898286 2003
40
A patient with dementia with Lewy bodies and codon 232 mutation of PRNP. 57
12451207 2002
41
Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology. 57
11890854 2002
42
[Diagnostic criteria of diffuse Lewy body disease]. 57
11068444 2000
43
Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. 6
10796875 2000
44
Familial dementia with Lewy bodies (DLB). 57
10505432 1999
45
Autosomal dominant diffuse Lewy body disease. 57
9705138 1998
46
Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 6
9554746 1998
47
Familial parkinsonism, dementia, and Lewy body disease: study of family G. 57
9382476 1997
48
Clinical features of familial diffuse Lewy body disease. 57
9276199 1997
49
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. 57
8909416 1996
50
Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 6
7789963 1995

Variations for Dementia, Lewy Body

ClinVar genetic disease variations for Dementia, Lewy Body:

6 (show all 25)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SNCB NM_003085.5(SNCB):c.208G>A (p.Val70Met) SNV Pathogenic 7025 rs104893936 GRCh37: 5:176053473-176053473
GRCh38: 5:176626472-176626472
2 SNCB NM_003085.5(SNCB):c.368C>A (p.Pro123His) SNV Pathogenic 7026 rs104893937 GRCh37: 5:176048219-176048219
GRCh38: 5:176621218-176621218
3 SNCA NM_000345.4(SNCA):c.136G>A (p.Glu46Lys) SNV Pathogenic 14010 rs104893875 GRCh37: 4:90749321-90749321
GRCh38: 4:89828170-89828170
4 SNCA SNCA, DUPLICATION Duplication Pathogenic 14011 GRCh37:
GRCh38:
5 SNCA NM_000345.4(SNCA):c.157G>A (p.Ala53Thr) SNV Pathogenic 14007 rs104893877 GRCh37: 4:90749300-90749300
GRCh38: 4:89828149-89828149
6 SNCA NC_000004.11:g.(?_90647315)_(90756838_?)dup Duplication Pathogenic 531846 GRCh37: 4:90647315-90756838
GRCh38: 4:89726164-89835687
7 SNCA NC_000004.11:g.(?_90647315)_(90756828_?)dup Duplication Pathogenic 639372 GRCh37: 4:90647315-90756828
GRCh38: 4:89726164-89835677
8 LOC106627981 , GBA NM_000157.4(GBA):c.1297G>T (p.Val433Leu) SNV Pathogenic 4292 rs80356769 GRCh37: 1:155205563-155205563
GRCh38: 1:155235772-155235772
9 LOC106627981 , GBA NM_000157.4(GBA):c.1226A>G (p.Asn409Ser) SNV Pathogenic 4290 rs76763715 GRCh37: 1:155205634-155205634
GRCh38: 1:155235843-155235843
10 LOC106627981 , GBA NM_000157.4(GBA):c.1604G>A (p.Arg535His) SNV Pathogenic 4311 rs75822236 GRCh37: 1:155204793-155204793
GRCh38: 1:155235002-155235002
11 LOC106627981 , GBA NM_000157.4(GBA):c.1504C>T (p.Arg502Cys) SNV Pathogenic 4295 rs80356771 GRCh37: 1:155204987-155204987
GRCh38: 1:155235196-155235196
12 LOC106627981 , GBA NM_000157.4(GBA):c.1342G>C (p.Asp448His) SNV Pathogenic 4293 rs1064651 GRCh37: 1:155205518-155205518
GRCh38: 1:155235727-155235727
13 LOC106627981 , GBA NM_000157.4(GBA):c.887G>A (p.Arg296Gln) SNV Pathogenic 4328 rs78973108 GRCh37: 1:155207244-155207244
GRCh38: 1:155237453-155237453
14 GBA NM_000157.4(GBA):c.115+1G>A SNV Pathogenic 93445 rs104886460 GRCh37: 1:155210420-155210420
GRCh38: 1:155240629-155240629
15 LOC106627981 , GBA NM_000157.4(GBA):c.1448T>C (p.Leu483Pro) SNV risk factor 4288 rs421016 GRCh37: 1:155205043-155205043
GRCh38: 1:155235252-155235252
16 LOC106627981 , GBA NM_000157.4(GBA):c.1226A>G (p.Asn409Ser) SNV risk factor 4290 rs76763715 GRCh37: 1:155205634-155205634
GRCh38: 1:155235843-155235843
17 SNCA NM_000345.4(SNCA):c.100A>G (p.Lys34Glu) SNV Uncertain significance 1003636 GRCh37: 4:90756719-90756719
GRCh38: 4:89835568-89835568
18 SNCA NM_000345.4(SNCA):c.150T>G (p.His50Gln) SNV Uncertain significance 162095 rs201106962 GRCh37: 4:90749307-90749307
GRCh38: 4:89828156-89828156
19 SNCA NM_000345.4(SNCA):c.47T>C (p.Val16Ala) SNV Uncertain significance 1009952 GRCh37: 4:90756772-90756772
GRCh38: 4:89835621-89835621
20 SNCA NM_000345.4(SNCA):c.*464C>A SNV Uncertain significance 1020728 GRCh37: 4:90647315-90647315
GRCh38: 4:89726164-89726164
21 SNCA NM_000345.4(SNCA):c.349C>A (p.Pro117Thr) SNV Uncertain significance 652694 rs145138372 GRCh37: 4:90650386-90650386
GRCh38: 4:89729235-89729235
22 SNCA NM_000345.4(SNCA):c.147G>A (p.Val49=) SNV Likely benign 767542 rs141859659 GRCh37: 4:90749310-90749310
GRCh38: 4:89828159-89828159
23 SNCA NM_000345.4(SNCA):c.156G>T (p.Val52=) SNV Likely benign 772345 rs148108612 GRCh37: 4:90749301-90749301
GRCh38: 4:89828150-89828150
24 SNCA NM_000345.4(SNCA):c.216G>A (p.Thr72=) SNV Likely benign 705925 rs144758871 GRCh37: 4:90743487-90743487
GRCh38: 4:89822336-89822336
25 SNCA NM_000345.4(SNCA):c.408C>T (p.Tyr136=) SNV Benign 350104 rs76642636 GRCh37: 4:90647794-90647794
GRCh38: 4:89726643-89726643

UniProtKB/Swiss-Prot genetic disease variations for Dementia, Lewy Body:

72
# Symbol AA change Variation ID SNP ID
1 SNCA p.Glu46Lys VAR_022703 rs104893875

Expression for Dementia, Lewy Body

Search GEO for disease gene expression data for Dementia, Lewy Body.

Pathways for Dementia, Lewy Body

Pathways related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 SNCAIP SNCA SLC6A3 PRNP PRKN PARK7
2
Show member pathways
12.64 TH SLC6A3 SLC18A2 MAOB ACHE
3
Show member pathways
12.56 SNCAIP SNCA SLC6A3 PRKN PARK7
4
Show member pathways
12.41 TH SNCAIP SNCA SLC6A3 SLC18A2 PRNP
5 11.98 SNCA MAPT APP APOE
6 11.86 TH SNCB SNCA PRNP PRKN PARK7
7
Show member pathways
11.85 TH SLC6A3 SLC18A2 MAOB
8 11.79 SLC18A2 MAOB CYP2D6 APP
9 11.73 TH SNCAIP SNCA SLC6A3 PRKN PARK7
10 11.46 PRNP MAPT APP
11 11.37 MAPT APP APOE
12
Show member pathways
11.33 TH SLC6A3 ACHE
13 11.24 CYP2D6 APOE ACHE
14 11.14 TH SNCA SLC6A3 PRKN PARK7 MAOB
15 11.11 TH SLC6A3 SLC18A2
16
Show member pathways
11 SLC6A3 BCHE ACHE
17
Show member pathways
10.98 TH SLC6A3 SLC18A2 MAOB
18 10.73 TH MAOB
19 10.66 TH ACHE

GO Terms for Dementia, Lewy Body

Cellular components related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.44 TH SNCG SNCB SNCAIP SNCA SLC6A3
2 mitochondrion GO:0005739 10.13 TH SNCA PRKN PARK7 MAPT MAOB
3 endoplasmic reticulum GO:0005783 10.11 PRNP PRKN PARK7 LRRK2 GBA CYP2D6
4 Golgi apparatus GO:0005794 10.08 SNCA PRNP PRKN LRRK2 GBA APP
5 synapse GO:0045202 10.03 SNCG SNCB SNCA PRKN PARK7 LRRK2
6 perinuclear region of cytoplasm GO:0048471 10 TH SNCG SNCA PRKN PARK7 APP
7 dendrite GO:0030425 9.97 TH PRNP MAPT LRRK2 APOE
8 neuron projection GO:0043005 9.91 TH SLC6A3 PRKN PARK7 MAPT LRRK2
9 membrane raft GO:0045121 9.88 SLC6A3 PRNP PARK7 MAPT LRRK2 APP
10 growth cone GO:0030426 9.8 SNCA MAPT LRRK2 APP
11 synaptic vesicle membrane GO:0030672 9.76 SNCA SLC18A2 LRRK2
12 synaptic vesicle GO:0008021 9.73 TH SNCAIP SNCA SLC18A2 LRRK2 APP
13 axon terminus GO:0043679 9.72 SNCG SNCB SNCA
14 inclusion body GO:0016234 9.62 SNCB SNCA PRNP LRRK2
15 Golgi-associated vesicle GO:0005798 9.6 LRRK2 APP
16 nuclear envelope lumen GO:0005641 9.58 BCHE APP
17 dopaminergic synapse GO:0098691 9.56 SLC6A3 SLC18A2
18 axon GO:0030424 9.56 TH SNCG SNCA SLC6A3 PARK7 MAPT
19 terminal bouton GO:0043195 9.55 TH SNCA SLC18A2 PRNP LRRK2
20 main axon GO:0044304 9.54 MAPT APP
21 neuronal cell body GO:0043025 9.28 TH SNCG SNCB SNCAIP SNCA SLC6A3

Biological processes related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.04 PRKN PARK7 MAPT APP APOE
2 chemical synaptic transmission GO:0007268 10.03 SNCG SNCB SNCA SLC18A2
3 response to drug GO:0042493 10.03 TH SNCA SLC6A3 MAOB BCHE
4 autophagy GO:0006914 9.98 PRKN PARK7 LRRK2 GBA
5 cellular protein metabolic process GO:0044267 9.98 SNCAIP SNCA PRKN APP APOE
6 neuron projection development GO:0031175 9.95 MAPT GBA APP APOE
7 cellular response to oxidative stress GO:0034599 9.92 SNCA PARK7 LRRK2
8 response to oxidative stress GO:0006979 9.92 PRNP PRKN LRRK2 APP APOE
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 SNCA PARK7 APP
10 locomotory behavior GO:0007626 9.91 TH SLC6A3 SLC18A2 PRKN APP
11 cholesterol metabolic process GO:0008203 9.9 GBA CYP2D6 APP APOE
12 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.89 PRKN LRRK2 GBA
13 regulation of autophagy GO:0010506 9.89 PRKN MAPT LRRK2
14 mitochondrion organization GO:0007005 9.89 PRKN PARK7 LRRK2 GBA
15 negative regulation of protein phosphorylation GO:0001933 9.89 SNCA PRNP PRKN PARK7 LRRK2
16 negative regulation of neuron apoptotic process GO:0043524 9.88 SNCB SNCA PRKN PARK7 GBA APOE
17 positive regulation of protein binding GO:0032092 9.87 PRKN LRRK2 APP
18 learning or memory GO:0007611 9.86 PRNP MAPT APP
19 learning GO:0007612 9.86 TH PRKN BCHE APP
20 protein destabilization GO:0031648 9.84 SNCA PRNP PRKN
21 positive regulation of neuron death GO:1901216 9.84 SNCA PRNP MAPT
22 negative regulation of neuron death GO:1901215 9.83 SNCA PRKN PARK7 LRRK2 GBA
23 synaptic vesicle endocytosis GO:0048488 9.82 SNCG SNCB SNCA
24 microglial cell activation GO:0001774 9.79 SNCA MAPT APP
25 cellular response to copper ion GO:0071280 9.79 SNCA PRNP APP
26 regulation of dopamine secretion GO:0014059 9.78 SNCG SNCA PRKN
27 regulation of neuron death GO:1901214 9.78 SNCG SNCB SNCA LRRK2
28 synapse organization GO:0050808 9.77 SNCG SNCB SNCA MAPT APP
29 regulation of neurotransmitter secretion GO:0046928 9.76 SNCG SNCAIP SNCA PRKN
30 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.75 PRKN PARK7 LRRK2
31 astrocyte activation GO:0048143 9.74 MAPT APP
32 cellular response to dopamine GO:1903351 9.74 PRKN LRRK2
33 negative regulation of protein processing GO:0010955 9.74 PRNP LRRK2
34 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.74 PARK7 LRRK2
35 locomotory exploration behavior GO:0035641 9.74 LRRK2 APOE
36 neurotransmitter biosynthetic process GO:0042136 9.74 TH SLC6A3 ACHE
37 cellular copper ion homeostasis GO:0006878 9.73 PRNP APP
38 supramolecular fiber organization GO:0097435 9.73 SNCA MAPT
39 amyloid fibril formation GO:1990000 9.73 MAPT APP
40 positive regulation of protein metabolic process GO:0051247 9.73 GBA APP
41 regulation of protein metabolic process GO:0051246 9.72 GBA APOE
42 amyloid precursor protein metabolic process GO:0042982 9.72 APOE ACHE
43 neurotransmitter catabolic process GO:0042135 9.72 MAOB ACHE
44 neuron projection maintenance GO:1990535 9.72 PRNP APP
45 negative regulation of oxidative stress-induced cell death GO:1903202 9.72 PRKN PARK7
46 negative regulation of long-term synaptic potentiation GO:1900272 9.72 PRNP APP APOE
47 modulation of age-related behavioral decline GO:0090647 9.71 PRNP APP
48 regulation of mitochondrial fission GO:0090140 9.71 MAPT LRRK2
49 intracellular distribution of mitochondria GO:0048312 9.71 MAPT LRRK2
50 dopamine biosynthetic process GO:0042416 9.71 TH SNCA SLC6A3

Molecular functions related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 protein-containing complex binding GO:0044877 9.88 SLC6A3 PRNP PRKN PARK7 APOE
2 microtubule binding GO:0008017 9.85 SNCA PRNP MAPT LRRK2
3 signaling receptor binding GO:0005102 9.85 SLC6A3 PARK7 GBA APP APOE
4 identical protein binding GO:0042802 9.77 TH SNCAIP SNCA PRNP PRKN PARK7
5 chaperone binding GO:0051087 9.73 PRNP PRKN MAPT
6 enzyme binding GO:0019899 9.7 TH SNCA PRKN PARK7 MAPT BCHE
7 copper ion binding GO:0005507 9.67 SNCA PRNP PARK7
8 amyloid-beta binding GO:0001540 9.62 PRNP BCHE APOE ACHE
9 phospholipase binding GO:0043274 9.57 SNCA PRKN
10 tubulin binding GO:0015631 9.56 PRNP PRKN MAPT LRRK2
11 monoamine transmembrane transporter activity GO:0008504 9.54 SLC6A3 SLC18A2
12 lipoprotein particle binding GO:0071813 9.52 MAPT APOE
13 dopamine binding GO:0035240 9.51 TH SLC6A3
14 cupric ion binding GO:1903135 9.43 PRNP PARK7
15 cholinesterase activity GO:0004104 9.4 BCHE ACHE
16 acetylcholinesterase activity GO:0003990 9.37 BCHE ACHE
17 cuprous ion binding GO:1903136 9.02 SNCG SNCB SNCA PRNP PARK7

Sources for Dementia, Lewy Body

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....